These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 6357058)

  • 1. Synthetic peptide immunogens as vaccines.
    Shinnick TM; Sutcliffe JG; Green N; Lerner RA
    Annu Rev Microbiol; 1983; 37():425-46. PubMed ID: 6357058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Synthetic peptide antigens for medical cell biology].
    Ayter S; Günalp A
    Mikrobiyol Bul; 1988 Jan; 22(1):76-85. PubMed ID: 3078790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide-elicited protein-reactive antibodies in molecular biology and medicine.
    Shinnick TM; Sutcliffe JG; Green N; Lerner RA
    J Invest Dermatol; 1984 Jul; 83(1 Suppl):112s-115s. PubMed ID: 6376645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tapping the immunological repertoire to produce antibodies of predetermined specificity.
    Lerner RA
    Nature; 1982 Oct; 299(5884):593-6. PubMed ID: 6181415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies that react with predetermined sites on proteins.
    Sutcliffe JG; Shinnick TM; Green N; Lerner RA
    Science; 1983 Feb; 219(4585):660-6. PubMed ID: 6186024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell activation and immunogenicity.
    Benjamini E; Wan AM; Langton BC; Andria ML
    Dev Biol Stand; 1986; 63():29-39. PubMed ID: 3527819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A synthetic peptide of influenza virus hemagglutinin as a model antigen and immunogen.
    Jackson DC; Brown LE
    Pept Res; 1991; 4(3):114-24. PubMed ID: 1823182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Use of muramyl dipeptides in models of synthetic vaccines].
    Audibert F
    Boll Ist Sieroter Milan; 1985; 64(2):95-102. PubMed ID: 3896261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of structure in antibody cross-reactivity between peptides and folded proteins.
    Craig L; Sanschagrin PC; Rozek A; Lackie S; Kuhn LA; Scott JK
    J Mol Biol; 1998 Aug; 281(1):183-201. PubMed ID: 9680484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel design of peptide immunogens: synthetic peptide with a reversible handle for the attachment to protein carriers.
    Vergara U; Tam JP
    Pept Res; 1989; 2(1):134-9. PubMed ID: 2520750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospect and prospects for synthetic vaccines: peptides, adjuvants and conjugates.
    Sela M
    Ann Sclavo Collana Monogr; 1984; 1(2):11-20. PubMed ID: 6085883
    [No Abstract]   [Full Text] [Related]  

  • 12. Method for the synthesis of highly pure vaccines using the lipid core peptide system.
    Moyle PM; Olive C; Good MF; Toth I
    J Pept Sci; 2006 Dec; 12(12):800-7. PubMed ID: 17131293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral peptide immunogens: current challenges and opportunities.
    Azizi A; Diaz-Mitoma F
    J Pept Sci; 2007 Dec; 13(12):776-86. PubMed ID: 17853502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Site-specific peptide vaccines for immunotherapy and immunization against chronic diseases, cancer, infectious diseases, and for veterinary applications.
    Wang CY; Walfield AM
    Vaccine; 2005 Mar; 23(17-18):2049-56. PubMed ID: 15755569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of muramyl peptides for the enhancement of synthetic vaccines.
    Chedid L; Audibert F; Jolivet M
    Dev Biol Stand; 1986; 63():133-40. PubMed ID: 3527818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Use of synthetic carriers and adjuvants for increasing the immunogenicity of a synthetic peptide from the CS-protein of Plasmodium falciparum].
    Ivanov BB; Meshcheriakova EA; Andronova TM; Ivanov VT
    Bioorg Khim; 1991 Jun; 17(6):732-46. PubMed ID: 1723268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide vaccine--a new approach to a safer foot-and-mouth disease virus vaccine.
    Pfaff E; Thiel HJ; Böhm HO; Leban J
    Arzneimittelforschung; 1987 Jan; 37(1):82-6. PubMed ID: 3032213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production and characterization of peptide antibodies.
    Trier NH; Hansen PR; Houen G
    Methods; 2012 Feb; 56(2):136-44. PubMed ID: 22178691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple variants in foot-and-mouse disease virus (FMDV) populations: the Achilles heel for peptide and rec. DNA vaccines?
    Barteling SJ; Woortmeyer R
    Dev Biol Stand; 1987; 66():511-21. PubMed ID: 3034708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic peptides: prospects for vaccine development.
    Milich DR
    Semin Immunol; 1990 Sep; 2(5):307-15. PubMed ID: 2134015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.